Market Overview - The Legal Cannabis Market has grown from USD 33.52 billion in 2024 to USD 42.91 billion in 2025, with a projected value of USD 144.18 billion by 2030, reflecting a compound annual growth rate (CAGR) of 27.52% [2][11]. - The market evolution is driven by legislative changes, consumer behavior, and technological advancements [2]. Industry Dynamics - Legislative changes and increasing consumer acceptance have led to a diverse range of products, including extracts and edibles, while regulatory bodies are enhancing quality control measures [3]. - Vertical integration and partnerships are essential for achieving scale and distribution advantages, with advances in cultivation improving yields and consistency [4]. - Federal developments are fostering optimism regarding interstate commerce and harmonized licensing and taxation frameworks [5]. Investment Trends - There is a noticeable shift towards ancillary services and strategic mergers and acquisitions, which are reshaping competitive landscapes and refining value creation across the supply chain [6]. - Decision-makers are gaining strategic insights to identify opportunities amid evolving consumer preferences and technological advancements [6]. Tariff Impact - New tariff structures in 2025 have increased costs for cultivation and processing, leading to reassessments of manufacturing locations and supplier networks [8]. - Retailers are facing margin pressures due to increased duties on imported machinery and packaging components, often passing costs to consumers [9]. - Regional operators are diversifying sourcing strategies to mitigate future tariff effects, fostering collaborative partnerships to maintain resilience [9]. Key Report Attributes - The report spans 193 pages, covering the forecast period from 2025 to 2030, with an estimated market value of USD 42.91 billion in 2025 and a forecasted value of USD 144.18 billion by 2030 [11].

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is delighted to announce that, further to the Company’s press release dated June 20, 2025 (the “June 20 Release”) respecting a financing term sheet, the Company has entered into a pre-development facility agreement dated July 10, 2025 (the “Facility Agreement”) with Trafigura Pte Ltd. (the “Lender”), pursuant to which the Lender has made available a facility of up to US$2.5m (the “Facility”). The Company ...

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is delighted to announce that, further to the Company’s press release dated June 20, 2025 (the “June 20 Release”) respecting a financing term sheet, the Company has entered into a pre-development facility agreement dated July 10, 2025 (the “Facility Agreement”) with Trafigura Pte Ltd. (the “Lender”), pursuant to which the Lender has made available a facility of up to US$2.5m (the “Facility”). The Company ...

Core Viewpoint - Atico Mining Corporation has successfully executed a loan amendment and restructuring with Trafigura, extending its existing secured credit agreement and outlining repayment terms for the outstanding principal amount of US$8.7 million [1][2]. Group 1: Loan Amendment and Restructuring - The outstanding principal amount of US$8.7 million will be repaid in two installments: US$2.7 million on July 25, 2025, and US$6 million on December 30, 2026 [2]. - The outstanding principal amount will accrue interest at a rate of SOFR plus 7.5% [2]. - The existing commercial concentrate purchase contract with Trafigura has been extended for two more years, covering 100% of the concentrate produced from the El Roble mine, with a minimum annual tonnage of 32,000 dry metric tons [2]. Group 2: Company Overview - Atico Mining Corporation is focused on exploring, developing, and mining copper and gold projects in Latin America [3]. - The company generates significant cash flow through the operation of the El Roble mine and is developing the high-grade La Plata VMS project in Ecuador [3]. - Atico is also pursuing additional acquisition opportunities in advanced stages [3].

北卡罗来纳州夏洛特与赞比亚卢萨卡, June 18, 2025 (GLOBE NEWSWIRE) -- 注册于特拉华州、专注于关键矿物开发的 Terra Metals Inc. 今日宣布两项任命：Tariq Abbasi 勋爵博士（获颁 MBE、DL、FRSA 头衔）加入董事会，Mark Donohue 先生出任首席运营官 (COO)。 此次高层任命正值公司准备最终敲定一项具有历史意义的 1 亿美元美赞合资企业之际，该协议定于明天在卢萨卡美国中心 (American Center) 签署。 Tariq Abbasi 勋爵博士是杰出的全球政治家，还是大伦敦地区副郡尉，拥有数十年的公共服务经验、外交影响力和董事会级别的经验。 此项任命标志着 Terra Metals 坚持原则性治理、建立国际公信力以及在即将对加拿大证券交易所 (CSE) 上市公司 Waskahigan Oil & Gas Corp. 进行反向收购 (RTO) 前做好资本市场战略准备。 “Abbasi 勋爵为我们的董事会带来了威望、公信力和全球影响力，”Terra Metals Inc. 董事长兼联合创始人 Mumena Mushinge 表示，“ ...

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of Me ...

Core Viewpoint - MediPharm Labs Corp. responds to a misleading press release from Apollo Technology Capital Corporation regarding the results of its annual and special meeting of shareholders, emphasizing that the meeting has not yet occurred and results are not available [1][2]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, utilizing a Good Manufacturing Practices certified facility [3]. - The company has invested in a research-driven team and state-of-the-art technology to deliver precision-dosed cannabis products to both domestic and international medical markets [3]. Regulatory Milestones - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [4]. - This GMP license is a crucial step towards the company's foreign drug manufacturing site registration with the US FDA [4]. Recent Acquisitions - In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded its reach to medical patients in Canada and internationally through various platforms and clinics [5]. - The acquisition included Harvest Medical Clinics in Canada, which provides consultations for medical cannabis education and prescriptions [5]. Compliance and Operations - The company operates in compliance with all applicable laws in the countries where it conducts business [6].

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“Glass Lewis”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees for the Board of Directo ...

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to support its current strategy and board nominees while rejecting the dissident group's proposals, emphasizing the success of its recent transformation and growth strategy [1][3][5]. Company Strategy and Performance - MediPharm has successfully transformed its operations over the past three years, focusing on strategic business lines, divesting non-core assets, and reducing operating costs, which has led to improved financial performance [3][4]. - The acquisition of VIVO Cannabis Inc. in April 2023 has accelerated international growth and created synergies, contributing to the company's positive trajectory [3][15]. - In Q1 2025, MediPharm reported an 87% revenue increase in the international medical market, achieving positive Adjusted EBITDA for the first time in over five years, with a gross profit margin of 38.7% [4][5]. Shareholder Engagement - The company is encouraging shareholders to vote using the GREEN proxy to support its board nominees and resolutions, emphasizing the importance of each vote [2][11]. - MediPharm has provided resources for shareholders to ensure their votes are counted and to disregard communications from the dissident group [12][18]. Dissident Group's Position - The dissident group, led by Apollo Technology Capital Corp. and former MediPharm CEO Patrick McCutcheon, has proposed alternative directors but has been criticized for lacking a substantive plan and for misrepresentations in their communications [6][7]. - Independent advisory firm ISS has concluded that the dissident group did not present a compelling case for change, reinforcing the company's position [7]. Historical Context - The company highlights the negative performance metrics during McCutcheon's tenure, including a 72% revenue decrease in 2020 and significant operating losses, contrasting this with the current leadership's improvements since 2022 [9][16].

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against t ...